세계의 피임약 시장 : 성장 기회, 성장 촉진요인, 산업 동향 분석 예측(2024-2032년)

The Global Contraceptives Market was valued at USD 23 billion in 2023 and is estimated to expand at a 6.3% CAGR between 2024 and 2032, spurred by the increasing emphasis on the prevention of sexually transmitted diseases (STDs) and growing awareness of innovative technologies for pregnancy prevention. As public health campaigns highlight the importance of safe sexual practices, more individuals are seeking effective contraceptive methods to reduce the risk of STDs and unintended pregnancies. Also, advancements in contraceptive technologies, such as non-invasive methods and personalized solutions, are attracting consumers, further boosting market growth, and broadening access to effective contraceptive options. The overall contraceptives industry is segregated based on product, age group, distribution channel, and region.

The devices segment achieved USD 16 billion in 2023 due to the increasing demand for long-lasting and highly effective options like intrauterine devices (IUDs) and contraceptive implants. These methods offer a higher success rate in preventing unintended pregnancies, which drives their preference over traditional alternatives. Additionally, advancements in technology and growing awareness about reproductive health further boost the adoption of contraceptive devices, solidifying their dominance in the market compared to other forms of contraception. The retail segment will establish USD 18.3 billion by 2032, driven by the increasing availability of products in pharmacies, drugstores, and online platforms.

Convenience, coupled with consumer preference for easy access, drives growth in this segment. Retail channels provide a variety of contraceptive options, allowing consumers to choose products that best suit their needs. Furthermore, promotional activities and health campaigns are enhancing consumer awareness, thereby reinforcing the retail segment's position in the contraceptives market. North America contraceptives industry held a USD 7.5 billion in 2023 and will experience a 4% CAGR through 2032, owing to the region's strong healthcare infrastructure, high awareness of family planning, and widespread use of advanced contraceptive methods.

Government initiatives supporting reproductive health, along with a growing preference for long-acting reversible contraceptives (LARCs), further propel market growth. Besides, the presence of leading manufacturers and well-established distribution networks enhances access to contraceptive products. North America's robust demand and advanced healthcare system make it the key contributor to the global contraceptives market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Favourable regulatory scenario in developed nations
    • 3.2.1.2 Growing inclination towards planned delayed pregnancy
    • 3.2.1.3 High unmet contraceptive needs in developing economies
    • 3.2.1.4 Growing prevalence of sexually transmitted diseases (STD)
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects of contraceptive drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Pricing trends
• 3.7 Consumer behavior analysis
• 3.8 Technology landscape
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Devices
  • 5.2.1 Condoms
    • 5.2.1.1 Male
    • 5.2.1.2 Female
  • 5.2.2 Intra-uterine devices
    • 5.2.2.1 Hormonal IUD
    • 5.2.2.2 Copper IUD
  • 5.2.3 Vaginal rings
  • 5.2.4 Subdermal implants
  • 5.2.5 Diaphragms
  • 5.2.6 Contraceptive sponges
• 5.3 Drugs
  • 5.3.1 Oral contraceptive pills
  • 5.3.2 Injectable contraceptives
  • 5.3.3 Topical contraceptives

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 15 - 44 years
• 6.3 Above 44 years

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Retail pharmacies
• 7.3 Hospital pharmacies
• 7.4 Online channels
• 7.5 Other distribution channels

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Afaxys, Inc.
• 9.2 Agile Therapeutics
• 9.3 Amneal Pharmaceuticals
• 9.4 Bayer AG
• 9.5 Church & Dwight Co., Inc.
• 9.6 Cooper Companies
• 9.7 Evofem Biosciences
• 9.8 HRA Pharma
• 9.9 Maxwellia Ltd
• 9.10 Mayer Laboratories, Inc.
• 9.11 Mithra Pharmaceuticals
• 9.12 Organon & Co.
• 9.13 Pfizer, Inc.
• 9.14 Reckitt Benckiser Group PLC
• 9.15 TherapeuticsMD, Inc.
• 9.16 Veru, Inc.